Kyverna Therapeutics, Inc.

KYTX Healthcare Biotechnology

Kyverna Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $7.0 million. In the quarter to June 2026, EPS grew 35.1%, free cash flow fell 27.1% and total debt rose 95,603.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

5.67 0.30 −5.03%
Market cap
$369.2M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
9.06 8.15 7.75 5.16

+8 more quarters

Net Debt/EBITDA
4.46 5.16 6.54 4.47
Debt/Equity
0.15 0.13 0.11 0.00
Free Cash Flow per Share
(0.67) (0.69) (0.76) (1.00)
Book value per Share
2.72 3.24 5.25 3.50
Free Cash Flow
(40.60) (41.60) (33.53) (43.25)
Other line items

Show all line items

Columns are period end dates